Literature DB >> 11292338

DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells.

C Arnaudeau1, C Lundin, T Helleday.   

Abstract

DNA double-strand breaks (DSB) represent a major disruption in the integrity of the genome. DSB can be generated when a replication fork encounters a DNA lesion. Recombinational repair is known to resolve such replication fork-associated DSB, but the molecular mechanism of this repair process is poorly understood in mammalian cells. In the present study, we investigated the molecular mechanism by which recombination resolves camptothecin (CPT)-induced DSB at DNA replication forks. The frequency of homologous recombination (HR) was measured using V79/SPD8 cells which contain a duplication in the endogenous hprt gene that is resolved by HR. We demonstrate that DSB associated with replication forks induce HR at the hprt gene in early S phase. Further analysis revealed that these HR events involve an exchange mechanism. Both the irs1SF and V3-3 cell lines, which are deficient in HR and non-homologous end joining (NHEJ), respectively, were found to be more sensitive than wild-type cells to DSB associated with replication forks. The irs1SF cell line was more sensitive in this respect than V3-3 cells, an observation consistent with the hypothesis that DSB associated with replication forks are repaired primarily by HR. The frequency of formation of DSB associated with replication forks was not affected in HR and NHEJ deficient cells, indicating that the loss of repair, rather than the formation of DSB associated with replication forks is responsible for the increased sensitivity of the mutant strains. We propose that the presence of DSB associated with replication forks rapidly induces HR via an exchange mechanism and that HR plays a more prominent role in the repair of such DSB than does NHEJ. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292338     DOI: 10.1006/jmbi.2001.4564

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  157 in total

1.  PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

Authors:  Brian McEllin; Cristel V Camacho; Bipasha Mukherjee; Brandon Hahm; Nozomi Tomimatsu; Robert M Bachoo; Sandeep Burma
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Pathways of DNA double-strand break repair during the mammalian cell cycle.

Authors:  Kai Rothkamm; Ines Krüger; Larry H Thompson; Markus Löbrich
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

Review 3.  Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Authors:  Sook Ryun Park; Alice Chen
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

Review 4.  Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

Authors:  Elena S Ratner; Alan C Sartorelli; Z Ping Lin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

5.  Reducing MCM levels in human primary T cells during the G(0)-->G(1) transition causes genomic instability during the first cell cycle.

Authors:  S J Orr; T Gaymes; D Ladon; C Chronis; B Czepulkowski; R Wang; G J Mufti; E M Marcotte; N S B Thomas
Journal:  Oncogene       Date:  2010-05-03       Impact factor: 9.867

Review 6.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

7.  High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.

Authors:  Ann Christin Parplys; Jasna Irena Seelbach; Saskia Becker; Matthias Behr; Agnieszka Wrona; Camilla Jend; Wael Yassin Mansour; Simon Andreas Joosse; Horst-Werner Stuerzbecher; Helmut Pospiech; Cordula Petersen; Ekkehard Dikomey; Kerstin Borgmann
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Authors:  David A Alagpulinsa; Srinivas Ayyadevara; Shmuel Yaccoby; Robert J Shmookler Reis
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

9.  Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability.

Authors:  Michal Schwartz; Eitan Zlotorynski; Michal Goldberg; Efrat Ozeri; Ayelet Rahat; Carlos le Sage; Benjamin P C Chen; David J Chen; Reuven Agami; Batsheva Kerem
Journal:  Genes Dev       Date:  2005-11-15       Impact factor: 11.361

10.  DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe.

Authors:  Amanda K Ashley; Meena Shrivastav; Jingyi Nie; Courtney Amerin; Kyle Troksa; Jason G Glanzer; Shengqin Liu; Stephen O Opiyo; Diana D Dimitrova; Phuong Le; Brock Sishc; Susan M Bailey; Greg G Oakley; Jac A Nickoloff
Journal:  DNA Repair (Amst)       Date:  2014-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.